Technical Analysis for IBRX - ImmunityBio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 6.42 | -2.87% | -0.19 |
Earnings due: Jun 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Crossed Above 50 DMA | Bullish | -2.87% | |
| Stochastic Buy Signal | Bullish | -2.87% | |
| Narrow Range Bar | Range Contraction | -2.87% | |
| Wide Bands | Range Expansion | -2.87% | |
| Oversold Stochastic | Weakness | -2.87% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 2 days ago |
| 10 DMA Resistance | 2 days ago |
| Up 5% | 2 days ago |
| Up 3% | 2 days ago |
| Fell Below 50 DMA | 2 days ago |
Get a Trading Assistant
- Earnings date: 06/11/2024
ImmunityBio, Inc. Description
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Cancer Treatment Cancer Immunotherapy Genomics Virotherapy Natural Killer Cell Lymphocytes Pelareorep
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.53 |
| 52 Week Low | 1.25 |
| Average Volume | 7,880,305 |
| 200-Day Moving Average | 4.10 |
| 50-Day Moving Average | 6.57 |
| 20-Day Moving Average | 7.50 |
| 10-Day Moving Average | 6.77 |
| Average True Range | 0.68 |
| RSI (14) | 43.50 |
| ADX | 19.86 |
| +DI | 26.41 |
| -DI | 22.19 |
| Chandelier Exit (Long, 3 ATRs) | 7.97 |
| Chandelier Exit (Short, 3 ATRs) | 8.34 |
| Upper Bollinger Bands | 9.13 |
| Lower Bollinger Band | 5.86 |
| Percent B (%b) | 0.17 |
| BandWidth | 43.59 |
| MACD Line | -0.09 |
| MACD Signal Line | 0.13 |
| MACD Histogram | -0.2243 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.34 | ||||
| Resistance 3 (R3) | 7.43 | 7.21 | 7.18 | ||
| Resistance 2 (R2) | 7.21 | 6.98 | 7.17 | 7.13 | |
| Resistance 1 (R1) | 6.82 | 6.84 | 6.71 | 6.73 | 7.08 |
| Pivot Point | 6.60 | 6.60 | 6.55 | 6.56 | 6.60 |
| Support 1 (S1) | 6.21 | 6.37 | 6.10 | 6.12 | 5.76 |
| Support 2 (S2) | 5.99 | 6.23 | 5.95 | 5.71 | |
| Support 3 (S3) | 5.60 | 5.99 | 5.66 | ||
| Support 4 (S4) | 5.51 |
